As anti‐VEGF therapy (e.g. bevacizumab) has been applied in the management of ovarian and cervical cancer, we advocate for research on whether NF‐κB pathway inhibitors could synergise with anti‐VEGF treatment to improve therapeutic efficacy. Here, NFKB1 is linked to cervical cancer.